This post was originally published on this site

Coronavirus vaccine stocks have soared over the past year. But it’s not too late to start investing in this dynamic space. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss a few points that will help you make the right decision for your portfolio.

[embedded content]

Olivia Zitkus: I did want to get your three takeaways for healthcare investors from this talk. Then I’ve got other stuff we can chat about if time allows. Three takeaways for us — whatever you think is most important from this chat.

Adria Cimino: I think that there’s still opportunity for latecomers. If a company’s a latecomer to the market, we shouldn’t say put them all in the same bag. But you have to look at each one carefully. Their success depends on many factors. So, we have to look at each individually. Some latecomers can be very successful. Others can be, well, forget it they’re too late. We have to look at each one individually. Second one would be: Don’t invest in a company for the COVID vaccine only. I think that’s what happened a lot with Ocugen (NASDAQ:OCGN) as we saw in the share movement. It was proof that they invested just for that, and that’s a shame. Ocugen, it’s worth taking a second look at the company. They do gene therapy for eye diseases but they’re very early stage. It’s good, if you want to invest in that company, to be investing in it for everything and to hold on for the long term. Also, my third point, I think, would be you should take a look at treatment makers if you want to invest also in the coronavirus space. We haven’t seen huge gains that vaccine stocks have had, but they are another area that could be very interesting. We’ve got treatment makers like Regeneron (NASDAQ:REGN) that haven’t gained as much, but they could gain in the long term.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.